Product Code: TMRGL69615
The report provides revenue of the global photodynamic therapy market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global photodynamic therapy market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the photodynamic therapy market.
The report delves into the competitive landscape of the global photodynamic therapy market. Key players operating in the global photodynamic therapy market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global photodynamic therapy market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Photodynamic Therapy Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Segment Definition
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Photodynamic Therapy Market Analysis and Forecast, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
- 5.1. Key Mergers & Acquisitions
- 5.2. Technological Advancements
- 5.3. Covid-19 Impact Analysis
6. Global Photodynamic Therapy Market Analysis and Forecast, by Product Type
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Product Type, 2017-2031
- 6.3.1. Photosensitizer Drugs
- 6.3.1.1. Porphyrin Derivative (PD)
- 6.3.1.1.1. Hematoporphyrin Derivative (HpD)
- 6.3.1.1.2. Benzoporphyrin Derivative (BPD)
- 6.3.1.1.3. Texaphyrins
- 6.3.1.1.4. Others
- 6.3.1.2. Aminolevulinic acid (ALA)
- 6.3.1.3. Chlorines
- 6.3.1.4. Others
- 6.3.2. Devices
- 6.3.2.1. Disposable Fiber Optic Light Delivery Devices (DFOLDD)
- 6.3.2.2. Diode Laser
- 6.4. Market Attractiveness Analysis, by Product Type
7. Global Photodynamic Therapy Market Analysis and Forecast, by Application
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Application, 2017-2031
- 7.3.1. Cancer
- 7.3.1.1. Basal Cell Carcinoma
- 7.3.1.2. Non-Small Cell Lung Cancer
- 7.3.1.3. Head & Neck Cancer
- 7.3.1.4. Others
- 7.3.2. Actinic Keratosis (AK)
- 7.3.3. Psoriasis
- 7.3.4. Acne
- 7.3.5. Others
- 7.4. Market Attractiveness Analysis, by Application
8. Global Photodynamic Therapy Market Analysis and Forecast, by End-user
- 8.1. Introduction & Definition
- 8.2. Key Findings / Developments
- 8.3. Market Value Forecast, by End-user, 2017-2031
- 8.3.1. Hospitals
- 8.3.2. C&DC
- 8.3.3. CCC
- 8.3.4. Others
- 8.4. Market Attractiveness Analysis, by End-user
9. Global Photodynamic Therapy Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness Analysis, by Region
10. North America Photodynamic Therapy Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Market Value Forecast, by Product Type, 2017-2031
- 10.2.1. Photosensitizer Drugs
- 10.2.1.1. Porphyrin Derivative (PD)
- 10.2.1.1.1. Hematoporphyrin Derivative (HpD)
- 10.2.1.1.2. Benzoporphyrin Derivative (BPD)
- 10.2.1.1.3. Texaphyrins
- 10.2.1.1.4. Others
- 10.2.1.2. Aminolevulinic acid (ALA)
- 10.2.1.3. Chlorines
- 10.2.1.4. Others
- 10.2.2. Devices
- 10.2.2.1. Disposable Fiber Optic Light Delivery Devices (DFOLDD)
- 10.2.2.2. Diode Laser
- 10.3. Market Value Forecast, by Application, 2017-2031
- 10.3.1. Cancer
- 10.3.1.1. Basal Cell Carcinoma
- 10.3.1.2. Non-Small Cell Lung Cancer
- 10.3.1.3. Head & Neck Cancer
- 10.3.1.4. Others
- 10.3.2. Actinic Keratosis (AK)
- 10.3.3. Psoriasis
- 10.3.4. Acne
- 10.3.5. Others
- 10.4. Market Value Forecast, by End-user, 2017-2031
- 10.4.1. Hospitals
- 10.4.2. C&DC
- 10.4.3. CCC
- 10.4.4. Others
- 10.5. Market Value Forecast, by Country, 2017-2031
- 10.5.1. U.S.
- 10.5.2. Canada
- 10.6. Market Attractiveness Analysis
- 10.6.1. By Product Type
- 10.6.2. By Application
- 10.6.3. By End-user
- 10.6.4. By Country
11. Europe Photodynamic Therapy Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Market Value Forecast, by Product Type, 2017-2031
- 11.2.1. Photosensitizer Drugs
- 11.2.1.1. Porphyrin Derivative (PD)
- 11.2.1.1.1. Hematoporphyrin Derivative (HpD)
- 11.2.1.1.2. Benzoporphyrin Derivative (BPD)
- 11.2.1.1.3. Texaphyrins
- 11.2.1.1.4. Others
- 11.2.1.2. Aminolevulinic acid (ALA)
- 11.2.1.3. Chlorines
- 11.2.1.4. Others
- 11.2.2. Devices
- 11.2.2.1. Disposable Fiber Optic Light Delivery Devices (DFOLDD)
- 11.2.2.2. Diode Laser
- 11.3. Market Value Forecast, by Application, 2017-2031
- 11.3.1. Cancer
- 11.3.1.1. Basal Cell Carcinoma
- 11.3.1.2. Non-Small Cell Lung Cancer
- 11.3.1.3. Head & Neck Cancer
- 11.3.1.4. Others
- 11.3.2. Actinic Keratosis (AK)
- 11.3.3. Psoriasis
- 11.3.4. Acne
- 11.3.5. Others
- 11.4. Market Value Forecast, by End-user, 2017-2031
- 11.4.1. Hospitals
- 11.4.2. C&DC
- 11.4.3. CCC
- 11.4.4. Others
- 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Italy
- 11.5.5. Spain
- 11.5.6. Rest of Europe
- 11.6. Market Attractiveness Analysis
- 11.6.1. By Product Type
- 11.6.2. By Application
- 11.6.3. By End-user
- 11.6.4. By Country/Sub-region
12. Asia Pacific Photodynamic Therapy Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Product Type, 2017-2031
- 12.2.1. Photosensitizer Drugs
- 12.2.1.1. Porphyrin Derivative (PD)
- 12.2.1.1.1. Hematoporphyrin Derivative (HpD)
- 12.2.1.1.2. Benzoporphyrin Derivative (BPD)
- 12.2.1.1.3. Texaphyrins
- 12.2.1.1.4. Others
- 12.2.1.2. Aminolevulinic acid (ALA)
- 12.2.1.3. Chlorines
- 12.2.1.4. Others
- 12.2.2. Devices
- 12.2.2.1. Disposable Fiber Optic Light Delivery Devices (DFOLDD)
- 12.2.2.2. Diode Laser
- 12.3. Market Value Forecast, by Application, 2017-2031
- 12.3.1. Cancer
- 12.3.1.1. Basal Cell Carcinoma
- 12.3.1.2. Non-Small Cell Lung Cancer
- 12.3.1.3. Head & Neck Cancer
- 12.3.1.4. Others
- 12.3.2. Actinic Keratosis (AK)
- 12.3.3. Psoriasis
- 12.3.4. Acne
- 12.3.5. Others
- 12.4. Market Value Forecast, by End-user, 2017-2031
- 12.4.1. Hospitals
- 12.4.2. C&DC
- 12.4.3. CCC
- 12.4.4. Others
- 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.5.1. China
- 12.5.2. India
- 12.5.3. Japan
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
- 12.6. Market Attractiveness Analysis
- 12.6.1. By Product Type
- 12.6.2. By Application
- 12.6.3. By End-user
- 12.6.4. By Country/Sub-region
13. Latin America Photodynamic Therapy Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Product Type, 2017-2031
- 13.2.1. Photosensitizer Drugs
- 13.2.1.1. Porphyrin Derivative (PD)
- 13.2.1.1.1. Hematoporphyrin Derivative (HpD)
- 13.2.1.1.2. Benzoporphyrin Derivative (BPD)
- 13.2.1.1.3. Texaphyrins
- 13.2.1.1.4. Others
- 13.2.1.2. Aminolevulinic acid (ALA)
- 13.2.1.3. Chlorines
- 13.2.1.4. Others
- 13.2.2. Devices
- 13.2.2.1. Disposable Fiber Optic Light Delivery Devices (DFOLDD)
- 13.2.2.2. Diode Laser
- 13.3. Market Value Forecast, by Application, 2017-2031
- 13.3.1. Cancer
- 13.3.1.1. Basal Cell Carcinoma
- 13.3.1.2. Non-Small Cell Lung Cancer
- 13.3.1.3. Head & Neck Cancer
- 13.3.1.4. Others
- 13.3.2. Actinic Keratosis (AK)
- 13.3.3. Psoriasis
- 13.3.4. Acne
- 13.3.5. Others
- 13.4. Market Value Forecast, by End-user, 2017-2031
- 13.4.1. Hospitals
- 13.4.2. C&DC
- 13.4.3. CCC
- 13.4.4. Others
- 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
- 13.6. Market Attractiveness Analysis
- 13.6.1. By Product Type
- 13.6.2. By Application
- 13.6.3. By End-user
- 13.6.4. By Country/Sub-region
14. Middle East & Africa Photodynamic Therapy Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Market Value Forecast, by Product Type, 2017-2031
- 14.2.1. Photosensitizer Drugs
- 14.2.1.1. Porphyrin Derivative (PD)
- 14.2.1.1.1. Hematoporphyrin Derivative (HpD)
- 14.2.1.1.2. Benzoporphyrin Derivative (BPD)
- 14.2.1.1.3. Texaphyrins
- 14.2.1.1.4. Others
- 14.2.1.2. Aminolevulinic acid (ALA)
- 14.2.1.3. Chlorines
- 14.2.1.4. Others
- 14.2.2. Devices
- 14.2.2.1. Disposable Fiber Optic Light Delivery Devices (DFOLDD)
- 14.2.2.2. Diode Laser
- 14.3. Market Value Forecast, by Application, 2017-2031
- 14.3.1. Cancer
- 14.3.1.1. Basal Cell Carcinoma
- 14.3.1.2. Non-Small Cell Lung Cancer
- 14.3.1.3. Head & Neck Cancer
- 14.3.1.4. Others
- 14.3.2. Actinic Keratosis (AK)
- 14.3.3. Psoriasis
- 14.3.4. Acne
- 14.3.5. Others
- 14.4. Market Value Forecast, by End-user, 2017-2031
- 14.4.1. Hospitals
- 14.4.2. C&DC
- 14.4.3. CCC
- 14.4.4. Others
- 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
- 14.6. Market Attractiveness Analysis
- 14.6.1. By Product Type
- 14.6.2. By Application
- 14.6.3. By End-user
- 14.6.4. By Country/Sub-region
15. Competition Landscape
- 15.1. Market Player - Competition Matrix (by tier and size of companies)
- 15.2. Market Share Analysis, by Company, 2021
- 15.3. Company Profiles
- 15.3.1. Galderma Laboratories, L.P.
- 15.3.1.1. Company Overview
- 15.3.1.2. Financial Overview
- 15.3.1.3. Product Portfolio
- 15.3.1.4. Business Strategies
- 15.3.1.5. Recent Developments
- 15.3.2. Biofrontera AG
- 15.3.2.1. Company Overview
- 15.3.2.2. Financial Overview
- 15.3.2.3. Product Portfolio
- 15.3.2.4. Business Strategies
- 15.3.2.5. 15.3.1.5. Recent Developments
- 15.3.3. Excel Lasers Limited
- 15.3.3.1. Company Overview
- 15.3.3.2. Financial Overview
- 15.3.3.3. Product Portfolio
- 15.3.3.4. Business Strategies
- 15.3.3.5. Recent Developments
- 15.3.4. LUMIBIRD group (Quantel Medical)
- 15.3.4.1. Company Overview
- 15.3.4.2. Financial Overview
- 15.3.4.3. Product Portfolio
- 15.3.4.4. Business Strategies
- 15.3.4.5. Recent Developments
- 15.3.5. Modulight Corporation
- 15.3.5.1. Company Overview
- 15.3.5.2. Financial Overview
- 15.3.5.3. Product Portfolio
- 15.3.5.4. Business Strategies
- 15.3.5.5. Recent Developments
- 15.3.6. Quest PharmaTech, Inc.
- 15.3.6.1. Company Overview
- 15.3.6.2. Financial Overview
- 15.3.6.3. Product Portfolio
- 15.3.6.4. Business Strategies
- 15.3.6.5. Recent Developments
- 15.3.7. Theralase Technologies, Inc.
- 15.3.7.1. Company Overview
- 15.3.7.2. Financial Overview
- 15.3.7.3. Product Portfolio
- 15.3.7.4. Business Strategies
- 15.3.7.5. Recent Developments
- 15.3.8. SUS Advancing Technology Co., Ltd.
- 15.3.8.1. Company Overview
- 15.3.8.2. Financial Overview
- 15.3.8.3. Product Portfolio
- 15.3.8.4. Business Strategies
- 15.3.8.5. Recent Developments